Overview

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Phase:

PHASE2

Details

Lead Sponsor:

Fundacin de investigacin HM

Collaborators:

Hospital Universitario 12 de Octubre
MFAR Clinical Research S.L.

Treatments:

Gemcitabine